§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇦🇪United Arab Emirates	🇺🇸United States
Authority & dossier
Regulatory authority	MoHAP	FDA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	None
Reference agencies	FDA, EMA (centralised), MHRA, Health Canada +3	—
Lead pathway (timeline & fees) — Federal Drug Registration (Standard) · New Drug Application — 505(b)(1)
Pathway name	Federal Drug Registration (Standard)	New Drug Application — 505(b)(1)
Approval timeline	180–365 days	304–365 days
Application fee	AED 8,500	USD 4,310,002
Annual renewal	AED 5,000	USD 416,734
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	No
Local responsible person	Yes	Yes
RP role	A UAE-resident Registered Pharmacist must be designated as Responsible Pharmacist for the Drug Store Licence. A separate Pharmacovigilance Officer is required and must report to MoHAP Pharmacovigilance.	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	4 designations	6 designations
Examples	Priority Review, Orphan Drug Pathway, Pandemic Emergency Use Authorisation +1	Priority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3
Post-approval lifecycle
Variations framework	Post-approval variations broadly aligned with EU Type IA/IB/II framework. Major variations require MoHAP approval; Minor follow tacit-approval procedures.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	Marketing authorisations valid for 5 years; renewal required 6 months before expiry. Renewal includes updated PSUR, sales data, and pharmacovigilance summary.	FDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	MoHAP Pharmacovigilance Department; PSURs aligned with ICH E2C(R2). Mandatory ICSR reporting via the National Pharmacovigilance Centre. UAE is a WHO-UMC member.	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60–90 days	30–30 days
GCP standard	ICH-GCP	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Regulated	Free pricing
Reference pricing	Yes	No
HTA required	No	No
HTA body	Emerging — DoH and DHA developing emirate-level HTA; no federal HTA agency yet	ICER (Institute for Clinical and Economic Review) — independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

United Arab EmiratesMoHAP
United StatesFDA

English submissions

United Arab EmiratesYes
United StatesYes

CTD accepted

United Arab EmiratesYes
United StatesYes

eCTD accepted

United Arab EmiratesYes
United StatesYes

Reliance pathway

United Arab EmiratesAvailable
United StatesNone

Reference agencies

United Arab EmiratesFDA, EMA (centralised), MHRA, Health Canada +3
United States—

Lead pathway (timeline & fees) — Federal Drug Registration (Standard) · New Drug Application — 505(b)(1)

Pathway name

United Arab EmiratesFederal Drug Registration (Standard)
United StatesNew Drug Application — 505(b)(1)

Approval timeline

United Arab Emirates180–365 days
United States304–365 days

Application fee

United Arab EmiratesAED 8,500
United StatesUSD 4,310,002

Annual renewal

United Arab EmiratesAED 5,000
United StatesUSD 416,734

Local representative

United Arab EmiratesRequired
United StatesNot required

Local manufacturing

United Arab EmiratesNot required
United StatesNot required

GMP inspection

United Arab EmiratesRequired
United StatesRequired

MAH & local presence

Local entity required

United Arab EmiratesYes
United StatesNo

Local responsible person

United Arab EmiratesYes
United StatesYes

RP role

United Arab EmiratesA UAE-resident Registered Pharmacist must be designated as Responsible Pharmacist for the Drug Store Licence. A separate Pharmacovigilance Officer is required and must report to MoHAP Pharmacovigilance.
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

United Arab Emirates4 designations
United States6 designations

Examples

United Arab EmiratesPriority Review, Orphan Drug Pathway, Pandemic Emergency Use Authorisation +1
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3

Post-approval lifecycle

Variations framework

United Arab EmiratesPost-approval variations broadly aligned with EU Type IA/IB/II framework. Major variations require MoHAP approval; Minor follow tacit-approval procedures.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

United Arab EmiratesMarketing authorisations valid for 5 years; renewal required 6 months before expiry. Renewal includes updated PSUR, sales data, and pharmacovigilance summary.
United StatesFDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

United Arab EmiratesMoHAP Pharmacovigilance Department; PSURs aligned with ICH E2C(R2). Mandatory ICSR reporting via the National Pharmacovigilance Centre. UAE is a WHO-UMC member.
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

United Arab EmiratesAvailable
United StatesAvailable

Compassionate Use

United Arab EmiratesAvailable
United StatesAvailable

Emergency Import

United Arab EmiratesAvailable
United StatesAvailable

Parallel Import

United Arab EmiratesNot permitted
United StatesNot permitted

Clinical trials

CTA approval

United Arab EmiratesRequired
United StatesRequired

Ethics approval

United Arab EmiratesYes
United StatesYes

CTA timeline

United Arab Emirates60–90 days
United States30–30 days

GCP standard

United Arab EmiratesICH-GCP
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

United Arab EmiratesRegulated
United StatesFree pricing

Reference pricing

United Arab EmiratesYes
United StatesNo

HTA required

United Arab EmiratesNo
United StatesNo

HTA body

United Arab EmiratesEmerging — DoH and DHA developing emirate-level HTA; no federal HTA agency yet
United StatesICER (Institute for Clinical and Economic Review) — independent, non-binding